港股異動 | 百威亞太(1876.HK)跌逾3% 一季度總銷量同比減少42.3%
格隆匯5月7日丨百威亞太(1876.HK)現報20.95港元,跌3.68%,暫成交1億港元,最新總市值2774億港元。百威亞太今日早間發佈截至2020年3月31日止三個月的未經審核業績稱,期內集團實現總銷量127720萬公升,同比減少42.3%,主要是受區內COVID-19疫情所影響,加上由於在2019年4月在韓國實施漲價前銷量增加,因此難以與2019年第一季度的數字相比。收入9.56億美元,收入由於銷量減少而下降39%。公告表示,在中國和韓國復甦推動下,集團的業務自3月中起每週持續改善。儘管因渠道和省份而有所差異,但集團對業務復甦仍持樂觀態度。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.